Categories: News

Wave Life Sciences to Webcast Conference Call of First Quarter 2022 Financial Results on May 12, 2022

CAMBRIDGE, Mass., May 05, 2022 (GLOBE NEWSWIRE) — Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that management will host a live webcast and conference call at 8:30 a.m. ET on Thursday, May 12, 2022, to discuss the company’s first quarter 2022 financial results and provide a business update.

The webcast of the conference call may be accessed by visiting “Events” at the investor relations section of the Wave Life Sciences corporate website: ir.wavelifesciences.com. The live teleconference may be accessed by dialing (866) 220-8068 (domestic) or (470) 495-9153 (international) and entering conference ID: 8092347. Following the conference call, an archived version of the call will be available on the website.

About Wave Life Sciences
Wave Life Sciences (Nasdaq: WVE) is a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases. Wave aspires to develop best-in-class medicines across multiple therapeutic modalities using PRISM, the company’s proprietary discovery and drug development platform that enables the precise design, optimization, and production of stereopure oligonucleotides. Driven by a resolute sense of urgency, the Wave team is targeting a broad range of genetically defined diseases so that patients and families may realize a brighter future. To find out more, please visit www.wavelifesciences.com and follow Wave on Twitter @WaveLifeSci.

Investor Contact:
Kate Rausch
617-949-4827
krausch@wavelifesci.com

Media Contact:
Alicia Suter
617-949-4817
asuter@wavelifesci.com

Staff

Recent Posts

Brainomix AI Technology Reveals Efficacy of Novel Neuroprotective Drug Candidate in Severe Acute Ischemic Stroke Patients

Brainomix 360 Stroke imaging was utilized to improve and standardize the grading of baseline stroke…

29 minutes ago

BC Platforms and GeneVault partner to unlock access to large-scale real-world and genomic data from under-represented populations

Partnership expands BC Platforms' global patient catchment to include an additional 48 million patient lives…

29 minutes ago

EPS Corporation Selects ArisGlobal’s LifeSphere® MultiVigilance

Prominent Japan CRO adopts new safety case processing system to further enhance compliance, automation, and…

29 minutes ago

DentScribe Joins Henry Schein One API Exchange as an Authorized Integration Vendor

DentScribe now safely and securely integrates with Dentrix to help dental practices build their best…

29 minutes ago

Hemogenyx Pharmaceuticals PLC – Issue of Equity

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE…

3 hours ago

1933 Industries Announces Maturity of Unsecured Convertible Debentures and Encourages Conversion to Support Continued Growth

VANCOUVER, BC / ACCESS Newswire / December 18, 2025 / 1933 Industries Inc. (the "Company"…

3 hours ago